Cardiovascular disease remains one of the leading causes of morbidity worldwide. While traditional risk factors such as cholesterol levels, blood pressure, diabetes, and smoking remain central, emerging research has identified another contributor: the gut microbiome.
The gut microbiome consists of trillions of microorganisms that influence digestion, immune signalling, and metabolic pathways. Alterations in microbial balance referred to as dysbiosis have been associated with systemic inflammation and cardiometabolic risk.
One of the most studied pathways linking gut bacteria to cardiovascular disease involves trimethylamine N-oxide (TMAO). Gut bacteria metabolise dietary nutrients such as choline and carnitine (commonly found in red meat and eggs) into trimethylamine (TMA), which is then converted in the liver to TMAO. Elevated plasma TMAO levels have been associated with increased risk of major adverse cardiovascular events.
Wang et al. (2011) first demonstrated this association in a landmark study published in Nature, showing that gut microbial metabolism of phosphatidylcholine promotes cardiovascular disease risk.
Subsequent clinical studies have reported correlations between higher circulating TMAO levels and cardiovascular events. However, it is important to clarify that association does not equal causation. The gut–heart axis remains an active area of research.
Atherosclerosis is now widely understood as an inflammatory condition of the arterial wall. Chronic low-grade inflammation contributes to plaque development and vascular dysfunction. Libby (2002), writing in Nature, described inflammation as central to the pathogenesis of atherosclerosis.
Emerging evidence suggests that gut microbial metabolites may influence inflammatory signalling pathways. However, clinical management of cardiovascular risk continues to focus on established factors including lipid levels, glycaemic control, blood pressure, weight management, and smoking cessation. Claims that gut therapies “clean arteries” or “reverse plaque” are not supported by high-quality human evidence and should be avoided.
Among modifiable factors, dietary fibre intake has some of the strongest evidence for cardiovascular benefit. A large systematic review and meta-analysis published in The Lancet found that higher intake of dietary fibre was associated with reduced risk of coronary heart disease, stroke, type 2 diabetes, and colorectal cancer (Reynolds et al., 2019).
Fermentable fibres are metabolised by gut bacteria into short-chain fatty acids (SCFAs), which may contribute to improved metabolic regulation and reduced inflammatory signalling. While probiotics are widely marketed, clinical benefit depends on strain specificity and individual context. From a preventive perspective, plant diversity, whole foods, and fibre-rich diets remain evidence-aligned recommendations.
Traditional systems of medicine, including Ayurveda, have long emphasised digestive function as foundational to systemic health. While classical concepts such as Agni and Ama are not biomedical diagnoses, they reflect a longstanding recognition that metabolic balance influences long-term wellbeing.
In contemporary clinical practice, evaluation of cardiovascular risk requires structured assessment rather than symptom interpretation alone. Individuals concerned about cardiometabolic health may benefit from a comprehensive cholesterol and lipid risk evaluation, particularly if there is family history, metabolic syndrome, or persistent abnormal laboratory findings.
Similarly, patients seeking a broader review of metabolic health parameters may consider an integrative cardiovascular and metabolic consultation that evaluates lifestyle factors, laboratory markers, and clinical history in a structured manner.
Current evidence supports an association between gut microbial activity and cardiovascular risk markers. However:
• The microbiome is one component of cardiovascular risk
• Gut interventions are adjunctive, not replacements for guideline-based therapy
• Lipid management, blood pressure control, diabetes care, and smoking cessation remain foundational
Patients should not discontinue prescribed medication based on microbiome discussions without physician supervision.
Wang Z et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. [LINK]
Libby P. (2002). Inflammation in atherosclerosis. Nature. [LINK]
Reynolds A et al. (2019). Carbohydrate quality and human health: systematic review and meta-analysis. The Lancet. [LINK]
This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Associations between gut microbiota and cardiovascular health are based on observational and mechanistic research and do not establish direct causation. Individuals with cardiovascular disease, elevated cholesterol, diabetes, or gastrointestinal disorders should seek personalised evaluation from a qualified healthcare professional. Lifestyle modifications should complement, not replace, standard medical care.
